Table 4.
Cancer sites and stages across study periods in 2020.
| Period (2020) | |||||
|---|---|---|---|---|---|
| Pre-COVID | COVID-Impacted | De-Escalation | Second Wave | 26 February–30 December | |
| Total, n (%) | 38/176 (21.59) | 20/126 (15.87) | 29/169 (17.16) | 93/504 (18.45) | 142/799 (17.77) |
| Mean (weekly) ± SD | 4.75 ± 1.28 | 2.22 ± 1.48 | 3.22 ± 1.72 | 3.58 ± 1.30 | 3.23 ± 1.49 |
| Percent reduction (95% CI) | −2.59 (−24.09–18.92) | 54.07 (32.45–75.70) | 30.03 (−1.89–61.94) | 17.55 (2.63–32.47) | 27.57 (15.91–39.23) |
| p-value | 0.8631 | 0.0005 | 0.0439 | 0.0028 | <0.0001 |
| Primary site/stage III-IV, n (%)/(%) | |||||
| Pancreatic | 7 (18.42)/5 (71.43) | 4 (20.00)/3 (75.00) | 6 (20.70)/4 (66.67) | 15 (16.13)/12 (80.00) | 25 (17.61)/19 (76.00) |
| Colorectal | 6 (15.79)/3 (50.00) | 3 (15.00)/1 (33.33) | 5 (17.24)/2 (40.00) | 18 (19.35)/10 (55.56) | 26 (18.31)/13 (50.00) |
| Hematological | 6 (15.79)/(n.a.) | 3 (15.00)/(n.a.) | 4 (13.79)/(n.a.) | 15 (16.13)/(n.a.) | 22 (15.49)/(n.a.) |
| Lung | 5 (13.16)/3 (60.00) | 2 (10.00)/1 (50.00) | 4 (13.79)/3 (75.00) | 13 (13.98)/11 (84.62) | 19 (13.38)/15 (78.95) |
| Upper gastrointestinal tract | 3 (7.89)/2 (66.67) | 1 (5.00)/1 (100.00) | 2 (6.90)/1 (50.00) | 6 (6.45)/6 (100.00) | 9 (6.34)/8 (88.89) |
| Renal and bladder | 2 (5.26)/1 (50.00) | 1 (5.00)/0 (0.00) | 2 (6.90)/1 (50.00) | 4 (4.30)/1 (25.00) | 7 (4.93)/2 (28.57) |
| Hepatobiliary | 2 (5.26)/2 (100.00) | 1 (5.00)/1 (100.00) | 1 (3.45)/1 (100.00) | 4 (4.30)/3 (75.00) | 6 (4.23)5 (83.33) |
| Breast | 2 (5.26)/1 (50.00) | 2 (10.00)/2 (100.00) | 2 (6.90)/2 (100.00) | 7 (7.53)/5 (71.43) | 11 (7.75)/9 (81.82) |
| Prostate | 2 (5.26)/2 (100.00) | 1 (5.00)/1 (100.00) | 1 (3.45)/1 (100.00) | 3 (3.23)/2 (66.67) | 5 (3.52)/4 (80.00) |
| Gynecological 1 | 1 (2.63)/0 (0.00) | 1 (5.00)/1 (100.00) | 1 (3.45)/1 (100.00) | 4 (4.30)/3 (75.00) | 6 (4.23)/5 (83.33) |
| Cancer of unknown primary site | 1 (2.63)/1 (100.00) | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 1 (1.08)/1 (100.00) | 1 (0.70)/1 (100.00) |
| Sarcoma | 1 (2.63)/1 (100.00) | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 2 (2.15)/1 (50.00) | 2 (1.41)/1 (50.00) |
| Neuroendocrine tumor | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 1 (3.45)/1 (100.00) | 0 (0.00)/(n.a.) | 1 (0.70)/1 (100.00) |
| Malignant melanoma | 0 (0.00)/(n.a.) | 1 (5.00)/1 (100.00) | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 1 (0.70)/1 (100.00) |
| Mesothelioma | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 0 (0.00)/(n.a.) | 1 (1.08)/1 (100.00) | 1 (0.70)1 (100.00) |
| Stage III-IV 2, total n (%) | 21/32 (65.63) | 12/17 (70.59) | 17/25 (68.00) | 56/78 (71.79) | 85/120 (70.83) |
1 Ovarian, endometrial, and cervical cancer; 2 Excluding hematological malignancies.